AVBP
ArriVent BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.94
+7.68%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 144.3M | 153.4M | 79.0M | 64.9M | 30.4M |
| SG&A Expense | 31.6M | 24.2M | 15.3M | 9.7M | 6.5M |
| General & Admin Expense | 31.6M | 24.2M | 15.3M | 9.7M | 6.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 175.9M | 177.5M | 94.3M | 74.6M | 36.9M |
| Cost and Expenses | 175.9M | 177.5M | 94.3M | 74.6M | 36.9M |
| Operating Income (EBIT) | (175.9M) | (177.5M) | (94.3M) | (74.6M) | (36.9M) |
| Non-Operating | |||||
| Interest Income | 12.2M | 11.2M | 13.8M | 5.3M | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 12.2M | 11.2M | 13.8M | 5.3M | — |
| Other Non-Op Income/Expense | 12.2M | 11.2M | 13.8M | 5.3M | — |
| Non-Operating Income (excl Interest) | (12.2M) | (11.2M) | (13.8M) | (5.3M) | — |
| EBT (Pre-Tax Income) | (163.7M) | (166.3M) | (80.5M) | (69.3M) | (36.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (163.7M) | (166.3M) | (80.5M) | (69.3M) | (36.9M) |
| Earnings from Cont. Ops | (163.7M) | (166.3M) | (80.5M) | (69.3M) | (36.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (163.7M) | (166.3M) | (80.5M) | (69.3M) | (36.9M) |
| Per Share | |||||
| Basic EPS | ($3.68) | ($4.32) | ($2.56) | ($2.17) | ($1.10) |
| Diluted EPS | ($3.68) | ($4.32) | ($2.56) | ($2.17) | ($1.10) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 47.6M | 38.5M | 31.5M | 32.0M | 33.5M |
| Diluted Shares Outstanding | 47.6M | 38.5M | 31.5M | 32.0M | 33.5M |
| Profitability Metrics | |||||
| EBITDA | (163.7M) | (166.3M) | (80.5M) | (69.3M) | — |
| D&A | — | — | — | — | 36.9M |
| EBIT | (163.7M) | (166.3M) | (80.5M) | (69.3M) | (36.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026